Novo Nordisk A/S
NVODrugs in Pipeline
117
Phase 3 Programs
86
Upcoming Catalysts
22
Next Catalyst
Mar 31, 2026
3dMarket Overview
Stock performance and key metrics
24 upcoming, 0 past
Partnership - Semaglutide
Novo Nordisk announced a partnership with telehealth company Hims & Hers to expand U.S. patient access to FDA-approved semaglutide medicines, effective later in March 2026, in response to shifts in their GLP-1 business model.
23 more catalysts beyond 14 days
Start a 48h free trial to see all upcoming catalysts
basal insulin
Diabetes
Semaglutide 1.0 mg
Obesity
Tirzepatide
Diabetes Mellitus, Type 2
Semaglutide 1 mg
Diabetes Mellitus, Type 2
insulin lispro
Diabetes
Semaglutide J
Diabetes Mellitus, Type 2
turoctocog alfa pegol (N8-GP)
Haemophilia A
DCR-PHXC
Primary Hyperoxaluria Type 1 (PH1)
exenatide
Diabetes
repaglinide and metformin combination tablet
Diabetes
NNC0487-0111
Obesity
Insulin glargine U100
Diabetes Mellitus, Type 2
repaglinide
Diabetes
biphasic human insulin 50
Diabetes
insulin human
Diabetes
inhaled human insulin
Diabetes
Etavopivat
Sickle Cell Disease
semaglutide 50 mg
Overweight and Obesity
CagriSema (Cagrilintide B and Semaglutide I)
Obesity
Canagliflozin
Diabetes
sulfonylurea
Diabetes
vatreptacog alfa (activated)
Congenital Bleeding Disorder
empagliflozin
Diabetes
biphasic insulin aspart 70
Diabetes
estradiol, 25 mcg
Menopause
insulin
Diabetes
17-beta estradiol
Genetic Disorder
estradiol, 10 mcg
Menopause
Semagludtide
Early Alzheimer's Disease
glibenclamide
Diabetes
eptacog alfa (activated)
Acquired Bleeding Disorder
Norditropin
Growth Hormone Disorder
biphasic human insulin 30
Diabetes
biphasic insulin aspart
Diabetes
Cagrilintide
Obesity or Overweight
Concizumab
Congenital Bleeding Disorder
sitagliptin
Diabetes
biphasic human insulin
Diabetes
Insulin Icodec
Diabetes Mellitus, Type 2
human insulin
Diabetes
insulin NPH
Diabetes
metformin
Diabetes
turoctocog alfa pegol
Congenital Bleeding Disorder
rosiglitazone
Diabetes
biphasic insulin aspart 50
Diabetes
DPP-4 inhibitor
Diabetes
NNC0365-3769 (Mim8)
Haemophilia A
Insulin Glargine 100U/mL
Diabetes Mellitus, Type 2
Norditropin®
Growth Hormone Deficiency in Children
Ziltivekimab B
Cardiovascular Risk
NNC0365-3769 (Mim8) PPX
Haemophilia A
Faster aspart
Diabetes Mellitus, Type 1
Liraglutide 3.0 mg
Metabolism and Nutrition Disorder
NNC6019-0001
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Etavopivat A
Sickle Cell Disease
sulphonylurea
Diabetes
nonacog beta pegol
Congenital Bleeding Disorder
glimepiride
Diabetes
NPH insulin
Diabetes
Turoctocog alfa
Haemostasis
Insuline glargine U100 (reduced)
Diabetes Mellitus, Type 2
Ziltivekimab
Heart Failure
pioglitazone
Diabetes
Oral semaglutide
Diabetes Mellitus, Type 2
0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)
Menopause
Faster-acting insulin aspart
Diabetes
Semaglutide 0.5 mg
Diabetes
somapacitan
Adult Growth Hormone Deficiency
human soluble insulin
Diabetes
oral anti-diabetic drug
Diabetes
Mim8
Haemophilia A
IcoSema
Type 2 Diabetes
insulin detemir
Diabetes
Semaglutide 2.4 mg
Obesity
Dulaglutide
Diabetes
somatropin
Growth Hormone Disorder
biphasic insulin aspart 30
Diabetes
activated recombinant human factor VII
Acquired Bleeding Disorder
Semaglutide
Obesity
insulin aspart
Diabetes
insulin degludec/liraglutide
Diabetes
insulin degludec
Diabetes
catridecacog
Congenital Bleeding Disorder
liraglutide
Diabetes
insulin degludec/insulin aspart
Diabetes
insulin glargine
Diabetes
CDR132L
Heart Failure
Cagrilintide 2.4 mg
Diabetes Mellitus, Type 2
NNC109-0012
Inflammation
Fast-acting insulin aspart
Diabetes Mellitus, Type 1
Semaglutide 2.4 mg and NNC0165-1875 2.0 mg
Obesity
sunitinib
Cancer
NNC0385-0434 A 15 mg
Atherosclerotic Cardiovascular Disease
orlistat
Metabolism and Nutrition Disorder
Semaglutide (administered by PDS290 pen)
Healthy Volunteers Diabetes Mellitus, Type 2
NNC0174-0833
Overweight
insulin 338 (GIPET I)
Diabetes
NNC0114-0006
Diabetes
COR-001
Anemia
NNC0662-0419
Overweight
NNC0194-0499
Alcohol-related Liver Disease
recombinant interleukin-21
Cancer
NNC 0151-0000-0000
Inflammation
Norditropin® FlexPro® pen
Growth Hormone Disorder
NDec - oral decitabine-tetrahydrouridine
Sickle Cell Disease
UBT251
Overweight
NNC126-0083
Growth Hormone Disorder
EX1000
Diabetes
activated recombinant human factor VII, long acting
Congenital Bleeding Disorder
NNC0487-0111 subcutanous
Type 2 Diabetes (T2D)
Semaglutide (administered by DV3396 pen)
Healthy Volunteers Diabetes Mellitus, Type 2
NNC0519-0130
Diabetes Mellitus, Type 2
NNC0194 0499 50 mg/mL
Non-alcoholic Steatohepatitis
nedosiran
Primary Hyperoxaluria
Dipeptidyl peptidase-4 inhibitors
Diabetes Mellitus, Type 2
NNC0090-2746
Diabetes
NNC0480-0389
Diabetes Mellitus, Type 2
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
basal insulin | Phase 3 | Diabetes | - | - |
Semaglutide 1.0 mg | Phase 3 | Obesity | - | - |
Tirzepatide | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Semaglutide 1 mg | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
insulin lispro | Phase 3 | Diabetes | - | - |
Semaglutide J | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
turoctocog alfa pegol (N8-GP) | Phase 3 | Haemophilia A | - | - |
DCR-PHXC | Phase 3 | Primary Hyperoxaluria Type 1 (PH1) | - | - |
exenatide | Phase 3 | Diabetes | - | - |
repaglinide and metformin combination tablet | Phase 3 | Diabetes | - | - |
NNC0487-0111 | Phase 3 | Obesity | - | - |
Insulin glargine U100 | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
repaglinide | Phase 3 | Diabetes | - | - |
biphasic human insulin 50 | Phase 3 | Diabetes | - | - |
insulin human | Phase 3 | Diabetes | - | - |
inhaled human insulin | Phase 3 | Diabetes | - | - |
Etavopivat | Phase 3 | Sickle Cell Disease | - | - |
semaglutide 50 mg | Phase 3 | Overweight and Obesity | - | - |
CagriSema (Cagrilintide B and Semaglutide I) | Phase 3 | Obesity | - | - |
Canagliflozin | Phase 3 | Diabetes | - | - |
sulfonylurea | Phase 3 | Diabetes | - | - |
vatreptacog alfa (activated) | Phase 3 | Congenital Bleeding Disorder | - | - |
empagliflozin | Phase 3 | Diabetes | - | - |
biphasic insulin aspart 70 | Phase 3 | Diabetes | - | - |
estradiol, 25 mcg | Phase 3 | Menopause | - | - |
insulin | Phase 3 | Diabetes | - | - |
17-beta estradiol | Phase 3 | Genetic Disorder | - | - |
estradiol, 10 mcg | Phase 3 | Menopause | - | - |
Semagludtide | Phase 3 | Early Alzheimer's Disease | - | - |
glibenclamide | Phase 3 | Diabetes | - | - |
eptacog alfa (activated) | Phase 3 | Acquired Bleeding Disorder | - | - |
Norditropin | Phase 3 | Growth Hormone Disorder | - | - |
biphasic human insulin 30 | Phase 3 | Diabetes | - | - |
biphasic insulin aspart | Phase 3 | Diabetes | - | - |
Cagrilintide | Phase 3 | Obesity or Overweight | - | - |
Concizumab | Phase 3 | Congenital Bleeding Disorder | - | - |
sitagliptin | Phase 3 | Diabetes | - | - |
biphasic human insulin | Phase 3 | Diabetes | - | - |
Insulin Icodec | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
human insulin | Phase 3 | Diabetes | - | - |
insulin NPH | Phase 3 | Diabetes | - | - |
metformin | Phase 3 | Diabetes | - | - |
turoctocog alfa pegol | Phase 3 | Congenital Bleeding Disorder | - | - |
rosiglitazone | Phase 3 | Diabetes | - | - |
biphasic insulin aspart 50 | Phase 3 | Diabetes | - | - |
DPP-4 inhibitor | Phase 3 | Diabetes | - | - |
NNC0365-3769 (Mim8) | Phase 3 | Haemophilia A | - | - |
Insulin Glargine 100U/mL | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Norditropin® | Phase 3 | Growth Hormone Deficiency in Children | - | - |
Ziltivekimab B | Phase 3 | Cardiovascular Risk | - | - |
NNC0365-3769 (Mim8) PPX | Phase 3 | Haemophilia A | - | - |
Faster aspart | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Liraglutide 3.0 mg | Phase 3 | Metabolism and Nutrition Disorder | - | - |
NNC6019-0001 | Phase 3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | - | - |
Etavopivat A | Phase 3 | Sickle Cell Disease | - | - |
sulphonylurea | Phase 3 | Diabetes | - | - |
nonacog beta pegol | Phase 3 | Congenital Bleeding Disorder | - | - |
glimepiride | Phase 3 | Diabetes | - | - |
NPH insulin | Phase 3 | Diabetes | - | - |
Turoctocog alfa | Phase 3 | Haemostasis | - | - |
Insuline glargine U100 (reduced) | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Ziltivekimab | Phase 3 | Heart Failure | - | - |
pioglitazone | Phase 3 | Diabetes | - | - |
Oral semaglutide | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) | Phase 3 | Menopause | - | - |
Faster-acting insulin aspart | Phase 3 | Diabetes | - | - |
Semaglutide 0.5 mg | Phase 3 | Diabetes | - | - |
somapacitan | Phase 3 | Adult Growth Hormone Deficiency | - | - |
human soluble insulin | Phase 3 | Diabetes | - | - |
oral anti-diabetic drug | Phase 3 | Diabetes | - | - |
Mim8 | Phase 3 | Haemophilia A | - | - |
IcoSema | Phase 3 | Type 2 Diabetes | - | - |
insulin detemir | Phase 3 | Diabetes | - | - |
Semaglutide 2.4 mg | Phase 3 | Obesity | - | - |
Dulaglutide | Phase 3 | Diabetes | - | - |
somatropin | Phase 3 | Growth Hormone Disorder | - | - |
biphasic insulin aspart 30 | Phase 3 | Diabetes | - | - |
activated recombinant human factor VII | Phase 3 | Acquired Bleeding Disorder | - | - |
Semaglutide | Phase 3 | Obesity | - | - |
insulin aspart | Phase 3 | Diabetes | - | - |
insulin degludec/liraglutide | Phase 3 | Diabetes | - | - |
insulin degludec | Phase 3 | Diabetes | - | - |
catridecacog | Phase 3 | Congenital Bleeding Disorder | - | - |
liraglutide | Phase 3 | Diabetes | - | - |
insulin degludec/insulin aspart | Phase 3 | Diabetes | - | - |
insulin glargine | Phase 3 | Diabetes | - | - |
CDR132L | Phase 2 | Heart Failure | - | - |
Cagrilintide 2.4 mg | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
NNC109-0012 | Phase 2 | Inflammation | - | - |
Fast-acting insulin aspart | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
Semaglutide 2.4 mg and NNC0165-1875 2.0 mg | Phase 2 | Obesity | - | - |
sunitinib | Phase 2 | Cancer | - | - |
NNC0385-0434 A 15 mg | Phase 2 | Atherosclerotic Cardiovascular Disease | - | - |
orlistat | Phase 2 | Metabolism and Nutrition Disorder | - | - |
Semaglutide (administered by PDS290 pen) | Phase 2 | Healthy Volunteers Diabetes Mellitus, Type 2 | - | - |
NNC0174-0833 | Phase 2 | Overweight | - | - |
insulin 338 (GIPET I) | Phase 2 | Diabetes | - | - |
NNC0114-0006 | Phase 2 | Diabetes | - | - |
COR-001 | Phase 2 | Anemia | - | - |
NNC0662-0419 | Phase 2 | Overweight | - | - |
NNC0194-0499 | Phase 2 | Alcohol-related Liver Disease | - | - |
recombinant interleukin-21 | Phase 2 | Cancer | - | - |
NNC 0151-0000-0000 | Phase 2 | Inflammation | - | - |
Norditropin® FlexPro® pen | Phase 2 | Growth Hormone Disorder | - | - |
NDec - oral decitabine-tetrahydrouridine | Phase 2 | Sickle Cell Disease | - | - |
UBT251 | Phase 2 | Overweight | - | - |
NNC126-0083 | Phase 2 | Growth Hormone Disorder | - | - |
EX1000 | Phase 2 | Diabetes | - | - |
activated recombinant human factor VII, long acting | Phase 2 | Congenital Bleeding Disorder | - | - |
NNC0487-0111 subcutanous | Phase 2 | Type 2 Diabetes (T2D) | - | - |
Semaglutide (administered by DV3396 pen) | Phase 2 | Healthy Volunteers Diabetes Mellitus, Type 2 | - | - |
NNC0519-0130 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
NNC0194 0499 50 mg/mL | Phase 2 | Non-alcoholic Steatohepatitis | - | - |
nedosiran | Phase 2 | Primary Hyperoxaluria | - | - |
Dipeptidyl peptidase-4 inhibitors | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
NNC0090-2746 | Phase 2 | Diabetes | - | - |
NNC0480-0389 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Diabetes
10 drugs in this indication
Diabetes Mellitus, Type 2
2 drugs in this indication
Congenital Bleeding Disorder
2 drugs in this indication
Obesity or Overweight
1 drug in this indication
Heart Failure
1 drug in this indication
Inflammation
1 drug in this indication
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
1 drug in this indication
Obesity
1 drug in this indication
Overweight
1 drug in this indication
Haemophilia A
1 drug in this indication
Healthy Volunteers Diabetes Mellitus, Type 2
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)